Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in children and adolescents in Africa: A randomised, placebo-controlled, multicentre Phase II clinical trial

Safety and immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in children in Sierra Leone: a randomised, double-blind, controlled trial

(2021) Muhammed O Afolabi et al.   LANCET INFECTIOUS DISEASES

Safety and long-term immunogenicity of the two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Sierra Leone: a combined open-label, non-randomised stage 1, and a randomised, double-blind, controlled stage 2 trial

(2021) David Ishola et al.   LANCET INFECTIOUS DISEASES

Safety and immunogenicity of 2-dose heterologous Ad26.ZEBOV, MVA-BN-Filo Ebola vaccination in healthy and HIV-infected adults: A randomised, placebo-controlled Phase II clinical trial in Africa

(2021) Houreratou Barry et al.   PLOS MEDICINE

Nonhuman primate to human immunobridging to infer the protective effect of an Ebola virus vaccine candidate

(2020) Ramon Roozendaal et al.   npj Vaccines

Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial

(2020) Andrew J Pollard et al.   LANCET INFECTIOUS DISEASES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Uganda and Tanzania

(2019) Zacchaeus Anywaine et al.   JOURNAL OF INFECTIOUS DISEASES

Randomized clinical trial examining safety and immunogenicity of heterologous prime-boost Ebola vaccines, Ad26.ZEBOV and MVA-BN-Filo: 12-month data from Nairobi, Kenya

(2019) Gaudensia Mutua et al.   JOURNAL OF INFECTIOUS DISEASES

Dynamics of the humoral immune response to a prime-boost Ebola vaccine: quantification and sources of variation

(2019) Chloé Pasin et al.   JOURNAL OF VIROLOGY

Use of the Filovirus Animal Non-Clinical Group (FANG) Ebola virus immuno-assay requires fewer study participants to power a study than the Alpha Diagnostic International assay

(2018) James Logue et al.   JOURNAL OF VIROLOGICAL METHODS

OUP accepted manuscript

(2018)   TRANSACTIONS OF THE ROYAL SOCIETY OF TROPICAL MEDICINE AND HYGIENE

A prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates

(2018) Benoit Callendret et al.   PLoS One

Can Ebola Virus Vaccines Have Universal Immune Correlates of protection?

(2018) Michelle Meyer et al.   TRENDS IN MICROBIOLOGY

Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)

(2017) Ana Maria Henao-Restrepo et al.   LANCET

Safety and Immunogenicity of Novel Adenovirus Type 26– and Modified Vaccinia Ankara–Vectored Ebola Vaccines

(2016) Iain D. Milligan et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Evaluation of Convalescent Plasma for Ebola Virus Disease in Guinea

(2016) Johan van Griensven et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody

(2016) D. Corti et al.   SCIENCE

Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp

(2014) Xiangguo Qiu et al.   NATURE

Ebola Virus Disease in West Africa — The First 9 Months of the Epidemic and Forward Projections

(2014)   NEW ENGLAND JOURNAL OF MEDICINE

Ebola Virus Disease and Children

(2014) Georgina Peacock et al.   JAMA Pediatrics

Antibodies are necessary for rVSV/ZEBOV-GP-mediated protection against lethal Ebola virus challenge in nonhuman primates

(2013) A. Marzi et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA